Abstract

Introduction. We developed a Social Observatory in the HealthCare (HC) & Pharma sector to better understand how the focus by Pharma companies on social communication has been implemented, following the new legislation that allows social advertising for over the counter (OTC) drugs.
 Methods and results. Activity on social networks between 01/06/2018 and 31/05/2019 has been analysed. The social channels monitored were: Facebook, Instagram, LinkedIn, Twitter and YouTube. Activity from 13 companies with HQ in Italy (Abiogen, Alfasigma, Angelini, Chiesi, Doc Generici, Dompé, Italfarmaco, Kedrion, Mediolanum, Menarini, Molteni, Recordati, Zambon) and 16 companies with HQ elsewhere (Abbvie, Amgen, Amway, Bayer, Gilead, GSK - Glaxo SmithKline, J&J/Janssen, Merck Serono, MSD, Nature’s Bounty, Novartis, P&G, Pfizer, Reckitt Benckiser, Roche, Sanofi) was captured and analysed using both quantitative and qualitative techniques. Italy HQ companies seem to use these channels to a lesser extent compared to companies HQs elsewhere. Examples of all the different Brand characters (i.e. Friendly, Playful, Warm, etc), tones (personal, honest, humble, etc) and purposes (engage, entertain, educate, etc) were captured and discussed in detail in the article.
 Conclusions. Pharma companies have a wide-ranging approach to communicating through social media. These data represent an important baseline to carefully analyse the evolution of social communication of HC&Pharma sector in Italy.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.